Affordable Access

Publisher Website

PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer

Authors
  • Elsharkawi, Sherif Mohamed
  • Elkaffash, Dalal
  • Moez, Pacint
  • El-Etreby, Nour
  • Sheta, Eman
  • Taleb, Raghda Saad Zaghloul
Type
Published Article
Journal
BMC Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 25, 2023
Volume
23
Identifiers
DOI: 10.1186/s12885-023-10549-3
PMID: 36698136
PMCID: PMC9878799
Source
PubMed Central
Keywords
Disciplines
  • Research
License
Unknown

Abstract

Background and objective Ovarian cancer is a leading cause of female mortality. Epigenetic changes occur in early stages of carcinogenesis and represent a marker for cancer diagnosis. Protocadherin 17 ( PCDH17 ) is a tumor suppressor gene involved in cell adhesion and apoptosis. The methylation of PCDH17 gene promoter has been described in several cancers including ovarian cancer. The aim of the study was to compare the methylation status of PCDH17 gene promoter between females diagnosed with epithelial ovarian cancer and a control group composed of normal and benign ovarian lesions. Methods Fifty female subjects were included in our study (25 ovarian cancer patients and 25 controls). DNA was extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissues of the subjects. Methylation levels for six CpG sites in the PCDH17 gene promoter were assessed by pyrosequencing. Results The methylation levels at five out of six sites were significantly higher in females with epithelial ovarian cancer compared to the control group. Moreover, the same applies for the mean methylation level with p value 0.018. Conclusion Methylation of PCDH17 gene promoter plays a role in ovarian carcinogenesis and can be used for diagnosis and early detection.

Report this publication

Statistics

Seen <100 times